Aliskiren Hemifumarate; Amlodipine Besylate Patent Expiration
Aliskiren Hemifumarate; Amlodipine Besylate is Used for treating high blood pressure. It was first introduced by Novartis Pharmaceuticals Corp
Aliskiren Hemifumarate; Amlodipine Besylate Patents
Given below is the list of patents protecting Aliskiren Hemifumarate; Amlodipine Besylate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Tekamlo | US8613949 | Galenical formulations of organic compounds | Dec 21, 2029 | Novartis |
Tekamlo | US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul 21, 2018
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate; Amlodipine Besylate's patents.
Latest Legal Activities on Aliskiren Hemifumarate; Amlodipine Besylate's Patents
Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate; Amlodipine Besylate.
Activity | Date | Patent Number |
---|---|---|
Expire Patent Critical | 31 Jan, 2022 | US8613949 |
Maintenance Fee Reminder Mailed Critical | 16 Aug, 2021 | US8613949 |
Patent Issue Date Used in PTA Calculation Critical | 24 Dec, 2013 | US8613949 |
Recordation of Patent Grant Mailed Critical | 24 Dec, 2013 | US8613949 |
Email Notification Critical | 05 Dec, 2013 | US8613949 |
Issue Notification Mailed Critical | 04 Dec, 2013 | US8613949 |
Application Is Considered Ready for Issue Critical | 22 Nov, 2013 | US8613949 |
Dispatch to FDC | 22 Nov, 2013 | US8613949 |
Issue Fee Payment Received Critical | 20 Nov, 2013 | US8613949 |
Issue Fee Payment Verified Critical | 20 Nov, 2013 | US8613949 |